End-of-day quote
Dhaka S.E.
06:00:00 2024-04-24 pm EDT
|
5-day change
|
1st Jan Change
|
62.8
BDT
|
-2.94%
|
|
-2.48%
|
-21.11%
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
9,688
|
7,769
|
9,828
|
12,613
|
20,592
|
18,626
|
Enterprise Value (EV)
1 |
16,967
|
16,385
|
22,475
|
28,989
|
39,038
|
40,327
|
P/E ratio
|
12.1
x
|
8.8
x
|
14.8
x
|
13.4
x
|
24.3
x
|
29.1
x
|
Yield
|
3.62%
|
4.52%
|
2.38%
|
2.23%
|
1.14%
|
1.26%
|
Capitalization / Revenue
|
0.93
x
|
0.89
x
|
1.29
x
|
1.16
x
|
2.13
x
|
1.34
x
|
EV / Revenue
|
1.63
x
|
1.88
x
|
2.94
x
|
2.68
x
|
4.04
x
|
2.9
x
|
EV / EBITDA
|
7.41
x
|
6.81
x
|
9.13
x
|
11.5
x
|
33.7
x
|
25.3
x
|
EV / FCF
|
-19.7
x
|
-10.5
x
|
-5.26
x
|
-792
x
|
-28.7
x
|
-13.2
x
|
FCF Yield
|
-5.09%
|
-9.56%
|
-19%
|
-0.13%
|
-3.48%
|
-7.57%
|
Price to Book
|
0.57
x
|
0.44
x
|
0.55
x
|
0.68
x
|
1.07
x
|
0.89
x
|
Nbr of stocks (in thousands)
|
234,000
|
234,000
|
234,000
|
234,000
|
234,000
|
234,000
|
Reference price
2 |
41.40
|
33.20
|
42.00
|
53.90
|
88.00
|
79.60
|
Announcement Date
|
11/27/18
|
11/30/19
|
12/1/20
|
11/29/21
|
12/11/22
|
12/15/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
10,423
|
8,705
|
7,648
|
10,833
|
9,662
|
13,927
|
EBITDA
1 |
2,291
|
2,407
|
2,461
|
2,529
|
1,160
|
1,597
|
EBIT
1 |
1,517
|
1,585
|
1,552
|
1,538
|
686.8
|
1,016
|
Operating Margin
|
14.55%
|
18.21%
|
20.3%
|
14.2%
|
7.11%
|
7.29%
|
Earnings before Tax (EBT)
1 |
960.8
|
1,037
|
802
|
1,193
|
1,063
|
841.3
|
Net income
1 |
801.8
|
882.4
|
665.7
|
939.1
|
846.1
|
640.9
|
Net margin
|
7.69%
|
10.14%
|
8.7%
|
8.67%
|
8.76%
|
4.6%
|
EPS
2 |
3.426
|
3.771
|
2.845
|
4.013
|
3.616
|
2.739
|
Free Cash Flow
1 |
-863
|
-1,567
|
-4,271
|
-36.58
|
-1,358
|
-3,052
|
FCF margin
|
-8.28%
|
-18%
|
-55.84%
|
-0.34%
|
-14.06%
|
-21.92%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
1.500
|
1.500
|
1.000
|
1.200
|
1.000
|
1.000
|
Announcement Date
|
11/27/18
|
11/30/19
|
12/1/20
|
11/29/21
|
12/11/22
|
12/15/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
7,280
|
8,616
|
12,647
|
16,377
|
18,446
|
21,700
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
3.177
x
|
3.579
x
|
5.138
x
|
6.476
x
|
15.91
x
|
13.59
x
|
Free Cash Flow
1 |
-863
|
-1,567
|
-4,271
|
-36.6
|
-1,358
|
-3,052
|
ROE (net income / shareholders' equity)
|
5.07%
|
5.27%
|
3.89%
|
5.73%
|
4.36%
|
3.22%
|
ROA (Net income/ Total Assets)
|
3.22%
|
3.21%
|
2.86%
|
2.43%
|
0.95%
|
1.26%
|
Assets
1 |
24,896
|
27,477
|
23,274
|
38,662
|
89,137
|
51,006
|
Book Value Per Share
2 |
72.90
|
75.20
|
76.80
|
79.80
|
82.50
|
89.00
|
Cash Flow per Share
2 |
2.170
|
0.3900
|
4.420
|
1.770
|
0.4500
|
0.5600
|
Capex
1 |
998
|
1,348
|
1,543
|
4,277
|
2,667
|
3,859
|
Capex / Sales
|
9.57%
|
15.49%
|
20.18%
|
39.48%
|
27.6%
|
27.71%
|
Announcement Date
|
11/27/18
|
11/30/19
|
12/1/20
|
11/29/21
|
12/11/22
|
12/15/23
|
|
1st Jan change
|
Capi.
|
---|
| -21.11% | 134M | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|